Jason Butler
Stock Analyst at Citizens
(4.71)
# 153
Out of 5,146 analysts
140
Total ratings
53.1%
Success rate
50.87%
Average return
Main Sectors:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRWD Ironwood Pharmaceuticals | Upgrades: Market Outperform | $8 | $3.79 | +111.08% | 2 | Jan 5, 2026 | |
| CYTK Cytokinetics | Maintains: Market Outperform | $78 → $88 | $70.10 | +25.53% | 17 | Dec 22, 2025 | |
| NSRX Nasus Pharma | Initiates: Market Outperform | $19 | $5.26 | +261.22% | 1 | Dec 18, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Market Outperform | $114 → $131 | $128.29 | +2.11% | 5 | Dec 16, 2025 | |
| PRTA Prothena Corporation | Maintains: Market Outperform | $11 → $19 | $8.97 | +111.82% | 12 | Dec 1, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Market Outperform | $91 → $92 | $70.36 | +30.76% | 14 | Nov 4, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Market Outperform | $9 → $12 | $4.09 | +193.40% | 8 | Oct 9, 2025 | |
| RAPP Rapport Therapeutics | Reiterates: Market Outperform | $28 | $28.99 | -3.41% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Market Outperform | $37 | $24.59 | +50.47% | 15 | Jun 26, 2025 | |
| GHRS GH Research | Reiterates: Market Outperform | $39 | $15.29 | +155.07% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $3.98 | +50.75% | 11 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $115 → $100 | $24.94 | +300.96% | 1 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $42 → $38 | $29.40 | +29.25% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $17 → $18 | $8.97 | +100.67% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $3.30 | +21.21% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $696 → $701 | $840.28 | -16.58% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $9 | $3.61 | +149.31% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $7.07 | +168.74% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $6.25 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $8.74 | +480,449.20% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $14.75 | +686.44% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $4.46 | +101.79% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.51 | - | 1 | Dec 2, 2020 |
Ironwood Pharmaceuticals
Jan 5, 2026
Upgrades: Market Outperform
Price Target: $8
Current: $3.79
Upside: +111.08%
Cytokinetics
Dec 22, 2025
Maintains: Market Outperform
Price Target: $78 → $88
Current: $70.10
Upside: +25.53%
Nasus Pharma
Dec 18, 2025
Initiates: Market Outperform
Price Target: $19
Current: $5.26
Upside: +261.22%
ABIVAX Société Anonyme
Dec 16, 2025
Maintains: Market Outperform
Price Target: $114 → $131
Current: $128.29
Upside: +2.11%
Prothena Corporation
Dec 1, 2025
Maintains: Market Outperform
Price Target: $11 → $19
Current: $8.97
Upside: +111.82%
Halozyme Therapeutics
Nov 4, 2025
Maintains: Market Outperform
Price Target: $91 → $92
Current: $70.36
Upside: +30.76%
Aquestive Therapeutics
Oct 9, 2025
Maintains: Market Outperform
Price Target: $9 → $12
Current: $4.09
Upside: +193.40%
Rapport Therapeutics
Jul 8, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $28.99
Upside: -3.41%
ACADIA Pharmaceuticals
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $37
Current: $24.59
Upside: +50.47%
GH Research
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $39
Current: $15.29
Upside: +155.07%
Jun 12, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $3.98
Upside: +50.75%
May 9, 2025
Maintains: Market Outperform
Price Target: $115 → $100
Current: $24.94
Upside: +300.96%
May 7, 2025
Maintains: Market Outperform
Price Target: $42 → $38
Current: $29.40
Upside: +29.25%
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $8.97
Upside: +100.67%
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $3.30
Upside: +21.21%
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $840.28
Upside: -16.58%
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $3.61
Upside: +149.31%
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $7.07
Upside: +168.74%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $6.25
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $8.74
Upside: +480,449.20%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $14.75
Upside: +686.44%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $4.46
Upside: +101.79%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $1.51
Upside: -